Concord Biotech Crescita futura
Future criteri di controllo 5/6
Concord Biotech is forecast to grow earnings and revenue by 25.5% and 19.1% per annum respectively. EPS is expected to grow by 25.3% per annum. Return on equity is forecast to be 24.5% in 3 years.
Informazioni chiave
25.5%
Tasso di crescita degli utili
25.3%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.4% |
| Tasso di crescita dei ricavi | 19.1% |
| Rendimento futuro del capitale proprio | 24.5% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 17 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2027 | 18,200 | 6,302 | 4,230 | N/A | 3 |
| 3/31/2026 | 15,090 | 4,938 | 3,127 | N/A | 4 |
| 3/31/2025 | 12,308 | 3,754 | 2,440 | N/A | 4 |
| 6/30/2024 | 10,379 | 3,132 | N/A | N/A | N/A |
| 3/31/2024 | 10,169 | 3,081 | 1,798 | 2,655 | N/A |
| 12/31/2023 | 9,706 | 3,046 | N/A | N/A | N/A |
| 9/30/2023 | 9,704 | 3,044 | 1,589 | 2,665 | N/A |
| 6/30/2023 | 8,670 | 2,453 | N/A | N/A | N/A |
| 3/31/2023 | 8,532 | 2,401 | 1,009 | 2,460 | N/A |
| 3/31/2022 | 7,129 | 1,749 | 526 | 2,081 | N/A |
| 3/31/2021 | 6,169 | 2,349 | -374 | 1,668 | N/A |
| 3/31/2020 | 5,123 | 1,691 | -6 | 1,548 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: CONCORDBIO's forecast earnings growth (25.5% per year) is above the savings rate (6.7%).
Guadagni vs Mercato: CONCORDBIO's earnings (25.5% per year) are forecast to grow faster than the Indian market (18.1% per year).
Guadagni ad alta crescita: CONCORDBIO's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: CONCORDBIO's revenue (19.1% per year) is forecast to grow faster than the Indian market (10.2% per year).
Ricavi ad alta crescita: CONCORDBIO's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: CONCORDBIO's Return on Equity is forecast to be high in 3 years time (24.5%)